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Abstract
Background: The discovery, more than ten years ago, of exchange proteins directly activated by cAMP (EPAC) as a new
family of intracellular cAMP receptors revolutionized the cAMP signaling research field. Extensive studies have revealed that
the cAMP signaling network is much more complex and dynamic as many cAMP-related cellular processes, previously
thought to be controlled by protein kinase A, are found to be also mediated by EPAC proteins. Although there have been
many important discoveries in the roles of EPACs greater understanding of their physiological function in cAMP-mediated
signaling is impeded by the absence of EPAC-specific antagonist.
Methodology/Principal Findings: To overcome this deficit, we have developed a fluorescence-based high throughput
assay for screening EPAC specific antagonists. Our assay is highly reproducible and simple to perform using the ‘‘mix and
measure’’ format. A pilot screening using the NCI-DTP diversity set library led to the identification of small chemical
compounds capable of specifically inhibiting cAMP-induced EPAC activation while not affecting PKA activity.
Conclusions/Significance: Our study establishes a robust high throughput screening assay that can be effectively applied
for the discovery of EPAC-specific antagonists, which may provide valuable pharmacological tools for elucidating the
biological functions of EPAC and for promoting an understanding of disease mechanisms related to EPAC/cAMP signaling.
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Introduction
cAMP-mediated signaling regulates a myriad of important
biological processes under both physiological and pathological
conditions. In multi-cellular eukaryotic organisms, the effects of
cAMP are transduced by two ubiquitously-expressed intracellular
cAMP receptors, the classic protein kinase A/cAMP-dependent
protein kinase (PKA/cAPK) and the more recently discovered
exchange protein directly activated by cAMP/cAMP-regulated
guanine nucleotide exchange factor (EPAC/cAMP-GEF) [1,2].
Since both PKA and EPAC are ubiquitously expressed in all
tissues, an increase in intracellular cAMP levels will lead to the
activation of both PKA and EPAC. Net physiological effects of
cAMP entail the integration of EPAC- and PKA-dependent
pathways in a spatial and temporal manner. Depending upon their
relative abundance, distribution and localization, as well as the
precise cellular environment, the two intracellular cAMP receptors
may act independently, converge synergistically, or oppose each
other in regulating a specific cellular function [3]. Therefore,
careful dissections of the individual role and relative contribution
of EPAC and PKA within the overall cAMP signaling in various
model systems are critical for further elucidating the mechanism of
cAMP signaling, as well as essential for developing novel
mechanism-based therapeutic strategies targeting specific cAMP-
signaling components.
Selective pharmacological probes, particularly inhibitors, have
been valuable tools for dissecting the physiological functions of
signaling molecules and the mechanism of signal transduction
pathways. Over the years, the cAMP analog, 8-(4-chloro-
phenylthio)-29-O-methyladenosine-39,59-cyclic monophosphate
(8-CPT-29-O-Me-cAMP/007), and its derivatives that selectively
activate EPAC over PKA have been developed based on
structure/sequence alignment analysis [4,5]. 8-CPT-29-O-Me-
cAMP exerts about 100-fold selectivity towards EPAC over PKA
and has become a widely used tool in EPAC-related research [4–
9]. Limitations of the 8-CPT-29-O-Me-cAMP class of compounds
include low membrane permeability and poor cellular potency
[10,11]. Recently, a caged 8-CPT-29-O-Me-cAMP derivative, 8-
CPT-29-O-Me-cAMP-AM, with enhanced membrane permeabil-
ity has been developed [10,11]. Despite this significant improve-
ment, the biological applications of 8-CPT-29-O-Me-cAMP -
related compounds are limited by their off-target effects inhibiting
phosphodiesterases (PDEs) in the cell, which causes elevation of
cAMP or/and cGMP and therefore indirect activation of PKA,
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EPAC-specific antagonists have been reported, and developing
EPAC-specific pharmacological probes to dissect the physiological
functions that EPAC play in the overall cAMP-mediated signaling
remains a major challenge within the research field. To bridge this
major gap in our knowledge, we have developed a robust high
throughput assay for the purpose of identifying small pharmaco-
logical probes that are capable of inhibiting EPAC functions in
vitro.
Results
Assay readout and signal intensity
To develop a sensitive and robust HTS assay for EPAC, we
decided to use fluorescent cyclic nucleotide analogs, which have
been used extensively to probe the interactions between cyclic
nucleotide and its receptors. Among all the fluorescent cAMP
analogs that we tested, 8-NBD-cAMP (8-(2-[7-Nitro-4-benzofur-
azanyl] aminoethyl-thio) adenosine-39,5 9-cyclic monophosphate),
gave the largest fluorescent change when titrated with purified full-
length EPAC2. As shown in Figure 1, the intrinsic fluorescence of
8-NBD-cAMP, alone in solution, is very low. Binding of 8-NBD-
cAMP to EPAC2 led to a dose-dependent increase in fluorescent
signal. A more than 100 fold increase in 8-NBD-cAMP fluorescent
signal was observed under near saturating EPAC2 concentration.
The fluorescence change seen with 8-NBD-cAMP can be reversed
by the addition of excess unlabelled cAMP, which competes with
8-NBD-cAMP in binding to EPAC2. On the other hand, the
magnitude of fluorescence increase associated with EPAC1
binding was much more modest, which is consistent with the
finding that binding of 8-NBD-cAMP to an isolated fragment of
the cAMP binding domain of EPAC1 leads to a maximal six-fold
increase in fluorescence intensity [13]. This very large reversible
fluorescence change of 8-NBD-cAMP during its binding to
EPAC2 protein made it an excellent readout for designing a
sensitive and robust HTS assay for EPAC antagonists. To define
the suitable protein and ligand concentrations for our screen, we
tested the concentration-dependence of the fluorescence signals in
96-well format by fixing the ratio of EPAC2/8-NBD-cAMP at
1:1.2. As shown in Figure S1, the fluorescence intensity signal
showed an excellent linearity as a function of EPAC2 concentra-
tion. We observed a signal-to-background ratio of 7 even at
0.025 mM of EPAC2 concentration. On the basis of these results,
concentrations at 0.05 mM and 0.06 mM for EPAC2/8-NBD-
cAMP, respectively, were used for subsequent experiments in 96-
well format.
Overall quality of the assay in 96-well format
To determine the suitability or quality of our proposed assay for
HTS, we performed preliminary studies in 96-well plates. 100 ml
of EPAC2/8-NBD-cAMP (0.05 mM/0.06 mM) was manually
pipetted into each well of the plate and fluorescent signals were
then monitored using a Molecular Devices SpectraMax M2
microplate reader. The background (control) signal of each well
was measured in the excess of cAMP (300 mM). Our assay showed
an excellent separation between sample and control signals
(Figure S2). To determine the reproducibility, between-plate
and day-to-day variations of the assay, independent tests were
performed. As demonstrated in Table 1, all major statistical
parameters showed excellent match between independent exper-
iments. The calculated Z9 scores were above 0.8. These results
suggest that our assay is highly reproducible with little between-
plate and day-to-day variations. To test the effect of DMSO, we
measured the fluorescent signal of EPAC2/8-NBD-cAMP in the
presence of various concentration of DMSO. As shown in
Table 2, the measured florescence signal in the presence of 1%
DMSO was within 5% of that in the absence of DMSO.
Therefore, our assay is well tolerated up to 1% of DMSO.
Dose-dependent responses to cAMP analogs
To further evaluate our assay, we determined the dose responses
of a small collection of known cAMP analogs: cAMP and 8-Cl-
cAMP can bind and activate EPAC while 29-deoxy-cAMP and
cXMP bind EPAC weakly and are incapable of activating EPAC.
As expected, cAMP and 8-Cl-cAMP led to significant dose-
dependent inhibitions of fluorescence signals while 29-deoxy-
cAMP and cXMP had minimal effects (Figure 2). Moreover, the
degree of signal decrease is consistent with the relative affinity of
these analogs to EPAC. For example, 8-Cl-cAMP led to a bigger
decrease in signal than cAMP at the same compounds concen-
trations as 8-Cl-cAMP binds EPAC tighter than cAMP. Based on
these results, we chose a single-dose compound concentration of
100 mM, at which concentration cAMP resulted in a ,80%
decrease in fluorescence signal, for HTS screening. Compounds
that cause more than 80% decrease in NBD fluorescence intensity
at 100 mM concentration are selected as initial positive hits and
evaluated further using secondary and counter-screening assays.
Screening of EPAC antagonists using a NCI-diversity set
library. As a validation step for translation of the assay to HTS,
we performed a pilot screening in 96-well format using the NCI
DTP (Developmental Therapeutics Program) diversity set library.
The NCI diversity set contains 1990 carefully selected small
molecules for their high chemical and pharmacological diversity
from the entire collection of 140,000 compounds at NCI. Majority
of the compounds did not affect the binding of 8-NBD-cAMP to
EPAC2 and about 18 compounds decreased the fluorescence
signal more than 80% at a test concentration of 100 mM. These 18
compounds were further tested individually using a secondary
functional assay that monitors the ability of EPAC to catalyze the
nucleotide exchange activity of Rap1. Three compounds
NCS45576, NCS119911 and NSC686365 were shown to be
able to inhibit EPAC2 GEF activity to basal levels at 25 mM
concentration in the presence of equal concentration of cAMP
(Figure 3A&B). Since these hits were obtained using an assay
developed against EPAC2, the ability of these compounds to
inhibit EPAC1 GEF activity was also tested in parallel. All three
Figure 1. Binding of 8-NBD-cAMP to EPAC1 and 2. (A) Change in
fluorescence when 8-NBD-cAMP (0.1 mM) is titrated with EPAC1 or
EPAC2. The fluorescence change can be reversed by the addition of
excess cAMP. Data are from three independent experiments with error
bars representing standard deviations.
doi:10.1371/journal.pone.0030441.g001
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nucleotide exchange at 25 mM concentration in the presence of
equal concentration of cAMP (Figure 3C).
To test the specificity of these compounds, we performed
counter-screening assays that measure type I and II PKA
holoenzyme activities, respectively. As shown in Figure 4,
25 mM of NCS45576 and NSC686365 did not significantly alter
cAMP-induced type I and II PKA holoenzymes activation while
NCS119911 blocked ,50% of type I or II PKA activities,
respectively. These results suggest that NCS45576 and
NSC686365 are EPAC specific inhibitors (ESI) that selectively
block cAMP-induced EPAC activation but do not inhibit cAMP-
mediated PKA activation.
To further characterize the relative potency of these indentified
EPAC antagonists, we determined the apparent IC50 of these
compounds in competing of 8-NBD-cAMP binding. As revealed
by Figure 5, NSC45576, NSC119911 and NSC686365 compet-
ed with 8-NBD-cAMP binding with apparent IC50 of 1.7, 3.8 and
7.9 mM, respectively, while cAMP competed with 8-NBD-cAMP
binding with a IC50 of 40 mM. Taken together, we have
established a robust HTS assay that is capable of identifying small
chemical probes specific for EPAC and not cross-reacting with
PKA.
Discussion
In this study, we developed a sensitive high throughput assay for
screening EPAC specific pharmacological probes utilizing the
environmentally-sensitive nitrobenzoxadiazole (NBD) fluorophore.
The assay takes advantage of the fact that the weakly fluorescent 8-
NBD-cAMP becomes brilliant fluorescently when it binds to
EPAC2. This large increase in fluorescent intensity allows us to
adapt the assay for high throughput screening using very low
EPAC2 and 8-NBD-cAMP concentrations. Furthermore, the
HTS assay can be performed effectively and simply using the
‘‘mix-and-measure’’ format with high reproducibility. When
performed pilot screen under the 96-well format, our screening
assay routinely provided an excellent Z9 score above 0.8.
As a validation step for translation of the assay to HTS, we
performed a pilot screen using the NCI DTP (Developmental
Therapeutics Program) diversity set library. The NCI diversity set
contains 1990 carefully selected small molecules for their high
chemical and pharmacological diversity from the entire collection
of 140,000 compounds at NCI. Our primary screening resulted in
an initial hit rate less than 1%. Subsequent validation using
individually ordered compounds and a secondary confirmation
assay that measured the guanine nucleotide exchange activity of
EPAC led to the identification of two EPAC antagonists. The
design of assay is particularly suitable for searching compounds
that directly compete with 8-NBD-cAMP in binding to EPAC2.
However, in theory if a chemical library with a large enough size is
used, the assay should also be capable of identifying allosteric
effectors that lock EPAC2 in conformations unfavorable for 8-
NBD-cAMP binding but are not in direct competition with probe.
Therefore, with its high sensitivity and broad dynamic range, our
assay should be able to be easily adapted to higher throughput
formats so allosteric inhibitors or even activators of EPAC can be
identified.
It should be emphasized that the assay described in this study
represents an initial effort in identifying EPAC-specific antago-
nists. Before small molecules identified using this assay can be
utilized as pharmacological probes for dissecting the physiological
functions of EPAC proteins, their pharmacological properties
should be carefully evaluated further to ensure that they don’t
disrupt other components of the cyclic nucleotide signaling
circuits. For example, while we have tested the effect of our
compounds on PKA, an immediately related cAMP signaling
molecule, their effects on other peripheral signaling molecules in
cells related to the EPAC pathway such as phosphodiesterases or
adenylyl cyclases should also be examined.
Table 2. Fluorescent signals of EPAC2/8-NBD-cAMP as a
function of DMSO concentration.
[DMSO] (%) 0 0.1 0.2 0.5 1.0
Signal (%) 100.061.8 100.962.1 99.963.5 96.260.9 96.263.6
doi:10.1371/journal.pone.0030441.t002
Figure 2. Dose-dependent response of selected cAMP analogs
of known activity. Active compounds: cAMP and 8-Cl-cAMP; inactive
compounds: 29-deoxy-cAMP and cXMP. Data are from three indepen-
dent experiments with error bars representing standard deviations.
doi:10.1371/journal.pone.0030441.g002
Table 1. Summary of assay statistic parameters* of independent experiments.
Experiments S sS CV (%) B sB S/B S/N Z9
Exp. 1 11,686 516 4.4 1,488 103 7.8 101.9 0.82
Exp. 2 11,016 375 3.3 1,526 81 7.2 105.4 0.85
*S: mean signal; sS: standard deviation of signal; CV: coefficient of variation; B: mean background (control); sB: standard deviation of background; S/B: signal-to-
background ratio; S/N: signal-to-noise ratio; Z9:Z 9 score as determined by 1{
(3sSz3sB)
(S{B) jj
[21].
doi:10.1371/journal.pone.0030441.t001
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(A) Chemical structures of identified EPAC inhibitors. cAMP-mediated
EPAC2 (B) or EPAC1 (C) GEF activity measured in the presence or
absence of EPAC antagonists: open circles, EPAC alone; closed circles:
EPAC in the presence of 25 mM cAMP; open squares, EPAC with 25 mM
cAMP and 25 mM NSC45576; open diamonds, EPAC with 25 mM cAMP
and 25 mM NSC119911; and open triangles up, EPAC with 25 mM cAMP
and 25 mM NSC686365. Similar results were obtained from three
independent experiments.
doi:10.1371/journal.pone.0030441.g003
Figure 4. Effects of NSC45576 and NSC119911 on PKA
activities. Type I (A) and II (B) PKA holoenzyme activities in the
presence of 0.1 mM cAMP: open circles, control; open triangles down,
25 mM H89; open squares, 25 mM NSC45576; open diamonds, 25 mM
NSC119911; and open triangles up, 25 mM NSC686365. Similar results
were obtained from three independent experiments.
doi:10.1371/journal.pone.0030441.g004
Figure 5. Relative potency of identified EPAC antagonists.
Dose-dependent competition of EPAC antagonists with 8-NBD-cAMP in
binding to EPAC2: open circles, cAMP control; open squares, 25 mM
NSC45576; open diamonds, 25 mM NSC119911; and open triangles up,
25 mM NSC686365. Similar results were obtained from three indepen-
dent experiments.
doi:10.1371/journal.pone.0030441.g005
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Reagents
8-NBD-cAMP, cXMP, 8-Cl-cAMP and 29-deoxy-cAMP were
purchased from BioLog Life Science Institute (Bremen, Germany).
MANT-GDP, a fluorescent GDP analog, was obtained from
Invitrogen (Carlsbad, CA, USA). All other reagents were
purchased through Sigma-Aldrich (St. Louse, MO, USA).
Compound libraries
Small chemical compounds from the Diversity set (1990
compounds), were obtained from the Open Chemical Repository
of National Cancer Institute Developmental Therapeutics Pro-
gram (DTP). Compounds were supplied in DMSO in 96-well
polypropylene plates and stored at 280uC. Replica daughter
plates were generated by diluting original stock plates 10-fold in
DMSO and used for screening.
Protein expression and purification
Recombinant EPAC1, EPAC2 and C-terminal truncated
Rap1B(1-167) were purified as described previously [14–16].
PKA RIa, RIIb and catalytic subunits were recombinantly
expressed in E. coli and purified to homogeneity as reported
[17]. Type I and II PKA holoenzymes were reconstituted from
individually purified recombinant PKA R and C subunits [18] All
proteins used in this study were at least 95% pure, as judged by
SDS PAGE.
Primary screen assay
Fluorescence intensity of 8-NBD-cAMP in complex with
EPAC2 has been used as the readout in the primary screen assay.
Primary screen of NCI DTP (Developmental Therapeutics
Program) diversity set library was performed in black 96-well
microplates from Corning Costar (Cambridge, MA, USA). Briefly,
50 nM EPAC2 solution was prepared in 20 mM Tris buffer,
pH 7.5, containing 150 mM NaCl, 1 mM EDTA and 1 mM
DDT. 8-NBD-cAMP was added to EPAC2 solution up to 60 nM
from 17 mM stock solution in water. Sample has been dispensed
into 96-well plate (100 ml/well) and test compounds were added
(1 ml/well) from 96-well mother plates. Test compounds were
added from 10 mM stock solutions in DMSO. Samples with
cAMP addition (1 ml/well from 30 mM stock solution in water)
and no additions have been used as a positive and a negative
control. Fluorescence intensity signal from 8-NBD probe was
recorded at room temperature before and after tested compounds
were added using SpectaMaxM2 microplate reader (Molecular
Devices, Silicon Valley, CA, USA) with excitation/emission
wavelengths set at 470/540 nm.
Secondary confirmation assay
Measurement of in vitro guanine nucleotide exchange factor
(GEF) activity of EPAC was adapted from a well known
fluorescence-based assay using a fluorescent guanine nucleotide
analog [19], and used as a functional confirmation assay for the
compounds identified from primary screen. Briefly, 0.2 mMo f
Rap1B(1–167) loaded with the fluorescent GDP analog (Mant-
GDP), was incubated with EPAC in 50 mM Tris buffer pH 7.5,
containing 50 mM NaCl, 5 mM MgCl2, 1 mM DTT and a 100-
fold molar excess of unlabeled GDP (20 mM) in the presence of
25 mM tested compound and 25 mM cAMP. Exchange of Mant-
GDP by GDP was measured as a decrease in fluorescence intensity
over time using a FluoroMax-3 spectrofluorometer with excita-
tion/emission wavelengths set at 366/450 nm. Typically, decay in
the fluorescence intensity was recorded over a time course of
6000 s with data points taken every 60 s.
Counter screening assay
Kinase activities of the type I and II PKA holoenzymes were
measured spectrophotometrically in a 96-well plate with a coupled
enzyme assay as described previously [20]. In this assay, the
formation of the ADP is coupled to the oxidation of NADH by the
pyruvate kinase/lactate dehydrogenase reactions so the reaction
rate can be determined by following the oxidation of NADH,
reflected by a decrease in absorbance at 340 nm. The kinase
reaction mixture (100 ml) contained 50 mM Mops (pH 7.0),
10 mM MgCl2, 1 mM ATP, 1 mM PEP, 0.1 mM NADH, 8 U
of pyruvate kinase, 15 U of lactate dehydrogenase, fixed amount of
type I or type II PKA holoenzyme and 0.1 mM cAMP, with or
without 25 mM of test compound. Reactions were pre-equilibrated
at room temperature and initiated by adding the Kemptide
substrate (final concentration 0.26 mM). PKA activities measured
in the presence of 25 mM H89, a selective PKA inhibitor, were
used as positive controls of PKA inhibition.
Supporting Information
Figure S1 Fluorescence intensities of Epac2/8-NBD-
cAMP as a function of protein concentrations. Fluores-
cence signals of Epac2/8-NBD-cAMP (filled circles) and 8-NBD-
cAMP (open circles) alone measured in a 96-well plate.
(TIF)
Figure S2 Typical assay data from a test run in 96-well
format. The solid horizontal lines show the means of the sample
of 0.05/0.06 mM of Epac2/8-NBD-cAMP (filled circles) and
background data in the presence of 300 mM of cAMP (open
circles). Broken lines display 3 stardard deviations (SD) from the
mean of each date set.
(TIF)
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